Christine Jacomet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christine Jacomet has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
Céline Lambert
Biostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France
4 shared publications- Céline Lambert
Biostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France
4 shared publications - Bruno Pereira
DRCI, Unité de Biostatistiques, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France
3 shared publications David Rey
Affiliation Le Trait d’Union, HIV-Infection Care Center, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
3 shared publications- Françoise Linard
Services des maladies infectieuses et tropicales, CHU de Tenon, CHU Hôtel-Dieu, AP-HP, Sorbonne Université, Paris, France
3 shared publications - Justine Prouteau
Service de maladies infectieuses, CHU de Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France
3 shared publications
Latest Publications
- Open Access
- 10 November 2025
- Published by Springer Nature in BMC Geriatrics
- Vol. 25 (1) , 1-14
Improving the care pathway for people living with HIV aged 70 years and older: the impact of geriatric screening in an infectious diseases unit (AUTO-HIV 70)
With increased life expectancy of people living with HIV comes increased rates of multimorbidity and frailty, which services are not currently managing well. A geriatric day hospital (GDH) screening program was offered in our infectious disease department for all people living with HIV aged 70 years and older coming for follow-up, with the aim to provide more holistic ageing care. In order to evaluate our professional practice, we assessed the proportion of participants who had a planned change in their care pathway following this screening, and describe the population who benefited from this GDH. From July 2021 up to January 2024, a cross-sectional study was performed. Demographic data was collected from participant’s medical records along with various validated geriatric screening scores. Changes in the care pathway included referrals to a health professional and/or a change in treatment. Changes were indicated by the results of the screening program, planned by the clinician if the changes were considered relevant and if the participant agreed, and finally implemented or not at the next consultation. The percentage of participants with a change in their care pathway following the geriatric screening test is presented with a 95% confidence interval. The factors associated with it were studied using the Chi-squared test or the Fisher’s exact test for categorical variables, and Student’s t test or Mann-Whitney test for continuous variables. A total of 63 people living with HIV, aged 75.2 ± 4.6 years, were included, 57.1% of whom had at least three comorbidities. According to the geriatric screening evaluations, a change in the care pathway was indicated in 56/63 (88.9%; 95%CI: 78.4 to 95.4%) people living with HIV, and planned by the doctor with the participant’s agreement in 34/63 (54.0%; 95%CI: 40.9 to 66.6%) participants. Factors associated with a planned change in the care pathway were Dat’AIDS mortality score (p=0.02), EPICES score (p=0.03), Fried frailty phenotype (p=0.007) and GFST (p=0.04). At least one planned change in the care pathway was implemented before the next consultation six months later in 30/63 (47.6%) people living with HIV. This study demonstrates the feasibility of organising geriatric screening in an infectious diseases unit. The proportion of changes that were implemented highlights the relevance of using these screening tests. It is, however, important to improve some of the screening tests used and raise awareness amongst people living with HIV and their doctors. This study was registered in the institution’s data processing register under number M23JC0704 and approved by the ethics committee (IRB00013412, “CHU de Clermont Ferrand IRB #1”, number IRB 2023CF089).
- 10 November 2025
- Published by Springer Nature in BMC Geriatrics
- Vol. 25 (1) , 1-14
Open AccessImproving the care pathway for people living with HIV aged 70 years and older: the impact of geriatric screening in an infectious diseases unit (AUTO-HIV 70)
With increased life expectancy of people living with HIV comes increased rates of multimorbidity and frailty, which services are not currently managing well. A geriatric day hospital (GDH) screening program was offered in our infectious disease department for all people living with HIV aged 70 years and older coming for follow-up, with the aim to provide more holistic ageing care. In order to evaluate our professional practice, we assessed the proportion of participants who had a planned change in their care pathway following this screening, and describe the population who benefited from this GDH. From July 2021 up to January 2024, a cross-sectional study was performed. Demographic data was collected from participant’s medical records along with various validated geriatric screening scores. Changes in the care pathway included referrals to a health professional and/or a change in treatment. Changes were indicated by the results of the screening program, planned by the clinician if the changes were considered relevant and if the participant agreed, and finally implemented or not at the next consultation. The percentage of participants with a change in their care pathway following the geriatric screening test is presented with a 95% confidence interval. The factors associated with it were studied using the Chi-squared test or the Fisher’s exact test for categorical variables, and Student’s t test or Mann-Whitney test for continuous variables. A total of 63 people living with HIV, aged 75.2 ± 4.6 years, were included, 57.1% of whom had at least three comorbidities. According to the geriatric screening evaluations, a change in the care pathway was indicated in 56/63 (88.9%; 95%CI: 78.4 to 95.4%) people living with HIV, and planned by the doctor with the participant’s agreement in 34/63 (54.0%; 95%CI: 40.9 to 66.6%) participants. Factors associated with a planned change in the care pathway were Dat’AIDS mortality score (p=0.02), EPICES score (p=0.03), Fried frailty phenotype (p=0.007) and GFST (p=0.04). At least one planned change in the care pathway was implemented before the next consultation six months later in 30/63 (47.6%) people living with HIV. This study demonstrates the feasibility of organising geriatric screening in an infectious diseases unit. The proportion of changes that were implemented highlights the relevance of using these screening tests. It is, however, important to improve some of the screening tests used and raise awareness amongst people living with HIV and their doctors. This study was registered in the institution’s data processing register under number M23JC0704 and approved by the ethics committee (IRB00013412, “CHU de Clermont Ferrand IRB #1”, number IRB 2023CF089).
- Open Access
- 6 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0311776
RESILSTIGMA. Resilience to self-stigmatization experienced by people living with HIV: Which self-reported factors improve awareness among health workers?
Background: Self-stigmatization is the process by which environmental stigmas are internalized. It leads to a decline in self-esteem, isolation, denial and risk behavior, and impairs quality of life. The aims of our study were to investigate the psychological, social and medical factors, in particular psychological flexibility and its defusion component, that are associated with resilience to self-stigmatization in people living with HIV (PLHIV), and to assess clinicians’ perceptions of the condition. Methods: A multicenter observational study was conducted in France using self-reports from PLHIV consulted between January 15, 2022 and June 15, 2022 and from professionals responsible for their care (study registration number 2021-A01588-33/SI:21.02814.000036). Self-stigmatization was measured by examining four domains: perceived stigma, anticipated stigma, internalized stigma and enacted stigma. Results: Self-reports were collected from 45 hospital wards, 666 from PLHIV, of whom 71% were male with a mean age of 53 +/- 12.6 years, and 131 from health professionals, of whom 72.5% were clinicians. A total of 279 PLHIV (42%) reported items of self-stigmatization. Multivariable analysis showed that self-stigmatization was significantly associated with major depression (OR: 3.59, 95% CI: 1.19 to 10.80, p = 0.02), psychological inflexibility (OR: 1.53, 95% CI: 1.19 to 1.97, p = 0.001), and parental support deficit in childhood (OR parental support: 0.63, 95% CI: 0.40 to 0.98, p = 0.04). Among the dimensions of psychological inflexibility associated with HIV self-stigma, only fusion was positively associated (p<0.01). The proportion of PLHIV experiencing self-stigma was accurately estimated by only 31 (23.7%) health workers. Those health workers who did not minimize the prevalence of self-stigmatization among PLHIV had no particular characteristics. Conclusions: While the best means to combat self-stigmatization would be a social-ecological approach, it is fundamental to target in parallel individual vulnerability and protective factors accessible to health workers’ interventions. Psychiatric care and/or the new cognitive-behavioral therapies could be offered more often as part of personalized care.
- 6 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0311776
Open AccessRESILSTIGMA. Resilience to self-stigmatization experienced by people living with HIV: Which self-reported factors improve awareness among health workers?
Background: Self-stigmatization is the process by which environmental stigmas are internalized. It leads to a decline in self-esteem, isolation, denial and risk behavior, and impairs quality of life. The aims of our study were to investigate the psychological, social and medical factors, in particular psychological flexibility and its defusion component, that are associated with resilience to self-stigmatization in people living with HIV (PLHIV), and to assess clinicians’ perceptions of the condition. Methods: A multicenter observational study was conducted in France using self-reports from PLHIV consulted between January 15, 2022 and June 15, 2022 and from professionals responsible for their care (study registration number 2021-A01588-33/SI:21.02814.000036). Self-stigmatization was measured by examining four domains: perceived stigma, anticipated stigma, internalized stigma and enacted stigma. Results: Self-reports were collected from 45 hospital wards, 666 from PLHIV, of whom 71% were male with a mean age of 53 +/- 12.6 years, and 131 from health professionals, of whom 72.5% were clinicians. A total of 279 PLHIV (42%) reported items of self-stigmatization. Multivariable analysis showed that self-stigmatization was significantly associated with major depression (OR: 3.59, 95% CI: 1.19 to 10.80, p = 0.02), psychological inflexibility (OR: 1.53, 95% CI: 1.19 to 1.97, p = 0.001), and parental support deficit in childhood (OR parental support: 0.63, 95% CI: 0.40 to 0.98, p = 0.04). Among the dimensions of psychological inflexibility associated with HIV self-stigma, only fusion was positively associated (p<0.01). The proportion of PLHIV experiencing self-stigma was accurately estimated by only 31 (23.7%) health workers. Those health workers who did not minimize the prevalence of self-stigmatization among PLHIV had no particular characteristics. Conclusions: While the best means to combat self-stigmatization would be a social-ecological approach, it is fundamental to target in parallel individual vulnerability and protective factors accessible to health workers’ interventions. Psychiatric care and/or the new cognitive-behavioral therapies could be offered more often as part of personalized care.
- 11 April 2024
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 40 (4) , 253-256
No Association Between HLA-B*57:01 and Prevalence and/or Outcome of Progressive Multifocal Leukoencephalopathy in a French Nationwide Human Immunodeficiency Virus Cohort
Among 34,351 patients living with human immunodeficiency virus with available HLA-B*57:01 included in the Dat'AIDS cohort, 194 patients (0.56%) had a history of progressive multifocal leukoencephalopathy (PML) and 1,746 (5.08%) were carriers of HLA-B*57:01. The frequency of HLA-B*57:01 was similar among patients with history of PML compared with patients without a history of PML (6.19% [95% confidence interval, CI 2.8%–9.6%] vs. 5.08% [95% CI 4.8%–5.3%]; p = .48). Among patients with PML, clinical and biological characteristics at PML diagnosis and the PML outcome were not different according to HLA-B*57:01 status.
- 11 April 2024
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 40 (4) , 253-256
No Association Between HLA-B*57:01 and Prevalence and/or Outcome of Progressive Multifocal Leukoencephalopathy in a French Nationwide Human Immunodeficiency Virus Cohort
Among 34,351 patients living with human immunodeficiency virus with available HLA-B*57:01 included in the Dat'AIDS cohort, 194 patients (0.56%) had a history of progressive multifocal leukoencephalopathy (PML) and 1,746 (5.08%) were carriers of HLA-B*57:01. The frequency of HLA-B*57:01 was similar among patients with history of PML compared with patients without a history of PML (6.19% [95% confidence interval, CI 2.8%–9.6%] vs. 5.08% [95% CI 4.8%–5.3%]; p = .48). Among patients with PML, clinical and biological characteristics at PML diagnosis and the PML outcome were not different according to HLA-B*57:01 status.
- 30 November 2023
- Published by Wiley in HIV Medicine
- Vol. 25 (4) , 454-461
Impact of screening programme to prevent anal cancer in high‐risk patients with HIV
Introduction: We assessed the impact of a nationwide screening programme to reduce the risk of anal cancer in a large cohort of high‐risk patients with HIV.Methods: From a large database from one referral centre, all high‐risk patients with HIV (men who have sex with men, history of anal or genital warts, or previous cervix human papillomavirus‐related lesions) who were eligible to enter the French anal cancer screening programme (2011–2020) were retrospectively included. Adherence to the screening programme was defined as no interval >18 months between two visits. Standardized management included perianal visualization and standard anoscopy with biopsies of macroscopic abnormalities.Results: Overall, 700 patients with HIV were included (median follow‐up 8.4 years [interquartile range 4.3–9.2] and 1491.6 patient‐years), and 336 had one or more proctology visit. A total of 13 patients were diagnosed with anal squamous cell carcinomas. The risk of anal cancer was higher with anal intra‐epithelial neoplasia grade 3 (AIN3; hazard ratio [HR] 44.5 [95% confidence interval {CI} 11.2–176.6], p < 0.001), AIN2 (HR 11.9 [95% CI 2.1–66.9], p = 0.005), or high‐grade dysplasia (HR 23.4 [95% CI 7.9–69.1], p < 0.001) than with low‐grade dysplasia or no lesion. Among the patients who were strictly adherent to the screening programme (4.6% [32/700]), we did not report any AIN or anal cancer, but we also did not observe any significant reduction in the risk of anal cancer (p = 0.51), AIN3 (p = 0.28), high‐grade dysplasia (p = 0.19), or any AIN lesions (p = 0.10) compared with non‐adherent patients. In contrast, screened patients were more likely to be diagnosed with anal warts (HR 3.71 [95% CI 2.14–6.42], p < 0.001).Conclusion: Macroscopic high‐grade dysplasia lesions are associated with a higher risk of developing anal cancer. Despite finding no cases of cancer during the screening programme, we also did not demonstrate a clear benefit from our screening programme for the prevention of anal cancer in high‐risk patients with HIV.
- 30 November 2023
- Published by Wiley in HIV Medicine
- Vol. 25 (4) , 454-461
Impact of screening programme to prevent anal cancer in high‐risk patients with HIV
Introduction: We assessed the impact of a nationwide screening programme to reduce the risk of anal cancer in a large cohort of high‐risk patients with HIV.Methods: From a large database from one referral centre, all high‐risk patients with HIV (men who have sex with men, history of anal or genital warts, or previous cervix human papillomavirus‐related lesions) who were eligible to enter the French anal cancer screening programme (2011–2020) were retrospectively included. Adherence to the screening programme was defined as no interval >18 months between two visits. Standardized management included perianal visualization and standard anoscopy with biopsies of macroscopic abnormalities.Results: Overall, 700 patients with HIV were included (median follow‐up 8.4 years [interquartile range 4.3–9.2] and 1491.6 patient‐years), and 336 had one or more proctology visit. A total of 13 patients were diagnosed with anal squamous cell carcinomas. The risk of anal cancer was higher with anal intra‐epithelial neoplasia grade 3 (AIN3; hazard ratio [HR] 44.5 [95% confidence interval {CI} 11.2–176.6], p < 0.001), AIN2 (HR 11.9 [95% CI 2.1–66.9], p = 0.005), or high‐grade dysplasia (HR 23.4 [95% CI 7.9–69.1], p < 0.001) than with low‐grade dysplasia or no lesion. Among the patients who were strictly adherent to the screening programme (4.6% [32/700]), we did not report any AIN or anal cancer, but we also did not observe any significant reduction in the risk of anal cancer (p = 0.51), AIN3 (p = 0.28), high‐grade dysplasia (p = 0.19), or any AIN lesions (p = 0.10) compared with non‐adherent patients. In contrast, screened patients were more likely to be diagnosed with anal warts (HR 3.71 [95% CI 2.14–6.42], p < 0.001).Conclusion: Macroscopic high‐grade dysplasia lesions are associated with a higher risk of developing anal cancer. Despite finding no cases of cancer during the screening programme, we also did not demonstrate a clear benefit from our screening programme for the prevention of anal cancer in high‐risk patients with HIV.
- Open Access
- 24 April 2022
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 2 (2) , 211-219
A proposed new paradigm for an anti-AIDS tolerogenic vaccine
Until now, despite 30 years of intensive work, the RV144 human immunodeficiency virus (HIV) vaccine trial initiated in 2003 remains so far the most protective vaccine prototype of all those tested (
- 24 April 2022
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 2 (2) , 211-219
Open AccessA proposed new paradigm for an anti-AIDS tolerogenic vaccine
Until now, despite 30 years of intensive work, the RV144 human immunodeficiency virus (HIV) vaccine trial initiated in 2003 remains so far the most protective vaccine prototype of all those tested (
- Open Access
- 8 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0265166
To what extent do people living with HIV, people on pre-exposure prophylaxis, doctors and pharmacists endorse 90-day dispensing of antiretroviral therapy in France?
The WHO 95-95-95 targets for 2030 do not imply that people living with HIV (PLHIV) achieve a good quality of life. The current 30-day dispensing interval for antiretroviral (ART) burdens the healthcare system. Lengthening dispensing intervals could alleviate this burden as well as enhance patient well-being. To capture perceptions on 90-day dispensing interval (90D) for ART from the perspective of PLHIV, people on pre-exposure prophylaxis (PrEP), doctors, and pharmacists. Multi-centre observational survey led in France from 16 to 20 October 2020, among doctors agreeing to participate via regional coordinated care organisations for HIV, all PLHIV or people on PrEP consulting these outpatient-clinic doctors, and pharmacists doing ART dispensing. The survey was completed by 220 doctors who saw 1087 people (999 PLHIV; 88 on PrEP) and 176 pharmacists from 55 centres. Among the PLHIV, 855 (85.6%, 95% CI: 83.2%–87.7%) and among the patients on PrEP, 70 (79.5%, 95% CI: 69.6%–87.4%) stated they would be interested in 90D. All in all, patients who were more likely to endorse 90D are those who opt exclusively for hospital dispensing (OR 3.22 [1.57–6.58]) and who rotate between hospital and community pharmacy dispensing (OR 3.29 [1.15–9.32]). Patients who were less likely to endorse 90-D were those who consult in a city located outside the 3 French high HIV prevalence regions (OR 0.66 [0.44–0.99]), receive 2 vs 1 pill QD regimens (OR 0.53 [0.31–0.91]), and anticipate at least one vs no limitation to 90D (OR 0.27 [0.17–0.42]). 90D was perceived as possible by 152 pharmacists (86.4%), including 8 (5%) without restriction, and 219 doctors (99.6%), including 42 (19.2%) regardless of PLHIV’s immunovirologic status or social conditions (health insurance coverage, access to housing or accommodation, access to rights, resources). Comparison of the benefits and limitations of a 90-day ART dispensing interval as perceived by PLHIV and people on PrEP, doctors and pharmacists shows that doctors anticipate a higher number of benefits than people on ART and/or pharmacists, chiefly that 90D would be more convenient and create less risk of drug shortages and that patients would gain autonomy and a better quality of life. Pharmacists were found to clearly perceive the economic benefits (90D would be less expensive) but anticipate more drawbacks than doctors and the people on ART themselves: more administrative burdens, more non-dispensing if doses get lost, harder to track adherence and more drug–drug interaction issues, and more work as they shall have to warn the patient of potential risks of shortages due to the cost of the stock. A clear majority of PLHIV, people on PrEP, doctors, and pharmacists endorsed 90D of ART. Most patients thought that 90D would be a good option, whereas most pharmacists and doctors thought that eligibility for 90D dispensing should depend on immunovirologic factors and social condition criteria. Moreover, pharmacists thought it would be necessary to commit regulatory resources and a better follow-up on adherence and drug–drug interactions.
- 8 April 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (4) , e0265166
Open AccessTo what extent do people living with HIV, people on pre-exposure prophylaxis, doctors and pharmacists endorse 90-day dispensing of antiretroviral therapy in France?
The WHO 95-95-95 targets for 2030 do not imply that people living with HIV (PLHIV) achieve a good quality of life. The current 30-day dispensing interval for antiretroviral (ART) burdens the healthcare system. Lengthening dispensing intervals could alleviate this burden as well as enhance patient well-being. To capture perceptions on 90-day dispensing interval (90D) for ART from the perspective of PLHIV, people on pre-exposure prophylaxis (PrEP), doctors, and pharmacists. Multi-centre observational survey led in France from 16 to 20 October 2020, among doctors agreeing to participate via regional coordinated care organisations for HIV, all PLHIV or people on PrEP consulting these outpatient-clinic doctors, and pharmacists doing ART dispensing. The survey was completed by 220 doctors who saw 1087 people (999 PLHIV; 88 on PrEP) and 176 pharmacists from 55 centres. Among the PLHIV, 855 (85.6%, 95% CI: 83.2%–87.7%) and among the patients on PrEP, 70 (79.5%, 95% CI: 69.6%–87.4%) stated they would be interested in 90D. All in all, patients who were more likely to endorse 90D are those who opt exclusively for hospital dispensing (OR 3.22 [1.57–6.58]) and who rotate between hospital and community pharmacy dispensing (OR 3.29 [1.15–9.32]). Patients who were less likely to endorse 90-D were those who consult in a city located outside the 3 French high HIV prevalence regions (OR 0.66 [0.44–0.99]), receive 2 vs 1 pill QD regimens (OR 0.53 [0.31–0.91]), and anticipate at least one vs no limitation to 90D (OR 0.27 [0.17–0.42]). 90D was perceived as possible by 152 pharmacists (86.4%), including 8 (5%) without restriction, and 219 doctors (99.6%), including 42 (19.2%) regardless of PLHIV’s immunovirologic status or social conditions (health insurance coverage, access to housing or accommodation, access to rights, resources). Comparison of the benefits and limitations of a 90-day ART dispensing interval as perceived by PLHIV and people on PrEP, doctors and pharmacists shows that doctors anticipate a higher number of benefits than people on ART and/or pharmacists, chiefly that 90D would be more convenient and create less risk of drug shortages and that patients would gain autonomy and a better quality of life. Pharmacists were found to clearly perceive the economic benefits (90D would be less expensive) but anticipate more drawbacks than doctors and the people on ART themselves: more administrative burdens, more non-dispensing if doses get lost, harder to track adherence and more drug–drug interaction issues, and more work as they shall have to warn the patient of potential risks of shortages due to the cost of the stock. A clear majority of PLHIV, people on PrEP, doctors, and pharmacists endorsed 90D of ART. Most patients thought that 90D would be a good option, whereas most pharmacists and doctors thought that eligibility for 90D dispensing should depend on immunovirologic factors and social condition criteria. Moreover, pharmacists thought it would be necessary to commit regulatory resources and a better follow-up on adherence and drug–drug interactions.
- Open Access
- 25 March 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (3) , e0261069
Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France
Background: We aimed to evaluate the incidence rates between 2010 and 2015 for invasive cervical cancer (ICC), breast cancer (BC), and colorectal cancer (CRC) in people living with HIV (PLWH) in France, and to compare them with those in the French general population. These cancers are targeted by the national cancer-screening program. Setting: This is a retrospective study based on the longitudinal data of the French Dat’AIDS cohort. Methods: Standardized incidence ratios (SIR) for ICC and BC, and incidence rates for all three cancers were calculated overall and for specific sub-populations according to nadir CD4 cell count, HIV transmission category, HIV diagnosis period, and HCV coinfection. Results: The 2010–2015 CRC incidence rate was 25.0 [95% confidence interval (CI): 18.6–33.4] per 100,000 person-years, in 44,642 PLWH (both men and women). Compared with the general population, the ICC incidence rate was significantly higher in HIV-infected women both overall (SIR = 1.93, 95% CI: 1.18–3.14) and in the following sub-populations: nadir CD4 ≤ 200 cells/mm3 (SIR = 2.62, 95% CI: 1.45–4.74), HIV transmission through intravenous drug use (SIR = 5.14, 95% CI: 1.93–13.70), HCV coinfection (SIR = 3.52, 95% CI: 1.47–8.47) and HIV diagnosis before 2000 (SIR = 2.06, 95% CI: 1.07–3.97). Conversely, the BC incidence rate was significantly lower in the study sample than in the general population (SIR = 0.56, 95% CI: 0.42–0.73). Conclusion: The present study showed no significant linear trend between 2010 and 2015 in the incidence rates of the three cancers explored in the PLWH study sample. Specific recommendations for ICC screening are still required for HIV-infected women and should focus on sub-populations at greatest risk.
- 25 March 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (3) , e0261069
Open AccessIncidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France
Background: We aimed to evaluate the incidence rates between 2010 and 2015 for invasive cervical cancer (ICC), breast cancer (BC), and colorectal cancer (CRC) in people living with HIV (PLWH) in France, and to compare them with those in the French general population. These cancers are targeted by the national cancer-screening program. Setting: This is a retrospective study based on the longitudinal data of the French Dat’AIDS cohort. Methods: Standardized incidence ratios (SIR) for ICC and BC, and incidence rates for all three cancers were calculated overall and for specific sub-populations according to nadir CD4 cell count, HIV transmission category, HIV diagnosis period, and HCV coinfection. Results: The 2010–2015 CRC incidence rate was 25.0 [95% confidence interval (CI): 18.6–33.4] per 100,000 person-years, in 44,642 PLWH (both men and women). Compared with the general population, the ICC incidence rate was significantly higher in HIV-infected women both overall (SIR = 1.93, 95% CI: 1.18–3.14) and in the following sub-populations: nadir CD4 ≤ 200 cells/mm3 (SIR = 2.62, 95% CI: 1.45–4.74), HIV transmission through intravenous drug use (SIR = 5.14, 95% CI: 1.93–13.70), HCV coinfection (SIR = 3.52, 95% CI: 1.47–8.47) and HIV diagnosis before 2000 (SIR = 2.06, 95% CI: 1.07–3.97). Conversely, the BC incidence rate was significantly lower in the study sample than in the general population (SIR = 0.56, 95% CI: 0.42–0.73). Conclusion: The present study showed no significant linear trend between 2010 and 2015 in the incidence rates of the three cancers explored in the PLWH study sample. Specific recommendations for ICC screening are still required for HIV-infected women and should focus on sub-populations at greatest risk.
- 1 March 2021
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (3) , 554-563
Spectrum and Incidence Trends of AIDS- and Non–AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort
Background: Cancer risk is higher in people living with HIV (PLWH) compared with the general population, and cancers related to age are expected to be most prevalent. Methods: We determined the spectrum and incidence rates of AIDS-defining cancers (ADC) and non–AIDS-defining cancers (NADC) and of lung, Hodgkin lymphoma (HL), head and neck (HNC), colon–rectum, anal, liver, breast, prostate, and urinary bladder cancers between January 2010 and December 2015 in the French Dat'AIDS cohort. Incidence rates were calculated by year and compared using the χ2 test for linear trend. Standardized incidence ratios [SIR (95% confidence interval)] were calculated relative to the French general population. Results: Among 44,642 patients, corresponding to 180,216.4 person-years (PY), 1,440 cancer cases occurred in 1,314 patients. ADC incidence was 191.4 (172.3–212.7)/105 PY and declined over time overall and in men, whereas NADC incidence was higher [548.8 (515.6–584.1)/105 PY] and did not change. In men, non-Hodgkin lymphoma was the most common cancer, but prostate cancer had the highest incidence among NADCs. Breast cancer was the most common cancer in women. SIRs were higher for cervical cancer [1.93 (1.18–3.14)], HNC in women [2.4 (1.4–4.2)], liver [overall: 3.8 (3.1–4.6); men: 3.2 (2.5–4.0); women: 12.9 (8.3–20.0)], and HL [overall: 13.8 (11.1–17.1); men: 16.2 (12.9–20.4); women: 6.2 (3.22–11.9)] but lower for lung [overall: 0.7 (0.6–0.9); men: 0.7 (0.5–0.8)], prostate [0.6 (0.5–0.7)], and breast cancers [0.6 (0.4–0.7)]. Conclusions: Spectrum of NADCs has changed, with prostate and breast cancers becoming the most common despite their lower SIR. Impact: These results confirm the need to maintain regular epidemiologic cancer monitoring in order to update screening guidelines.
- 1 March 2021
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (3) , 554-563
Spectrum and Incidence Trends of AIDS- and Non–AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort
Background: Cancer risk is higher in people living with HIV (PLWH) compared with the general population, and cancers related to age are expected to be most prevalent. Methods: We determined the spectrum and incidence rates of AIDS-defining cancers (ADC) and non–AIDS-defining cancers (NADC) and of lung, Hodgkin lymphoma (HL), head and neck (HNC), colon–rectum, anal, liver, breast, prostate, and urinary bladder cancers between January 2010 and December 2015 in the French Dat'AIDS cohort. Incidence rates were calculated by year and compared using the χ2 test for linear trend. Standardized incidence ratios [SIR (95% confidence interval)] were calculated relative to the French general population. Results: Among 44,642 patients, corresponding to 180,216.4 person-years (PY), 1,440 cancer cases occurred in 1,314 patients. ADC incidence was 191.4 (172.3–212.7)/105 PY and declined over time overall and in men, whereas NADC incidence was higher [548.8 (515.6–584.1)/105 PY] and did not change. In men, non-Hodgkin lymphoma was the most common cancer, but prostate cancer had the highest incidence among NADCs. Breast cancer was the most common cancer in women. SIRs were higher for cervical cancer [1.93 (1.18–3.14)], HNC in women [2.4 (1.4–4.2)], liver [overall: 3.8 (3.1–4.6); men: 3.2 (2.5–4.0); women: 12.9 (8.3–20.0)], and HL [overall: 13.8 (11.1–17.1); men: 16.2 (12.9–20.4); women: 6.2 (3.22–11.9)] but lower for lung [overall: 0.7 (0.6–0.9); men: 0.7 (0.5–0.8)], prostate [0.6 (0.5–0.7)], and breast cancers [0.6 (0.4–0.7)]. Conclusions: Spectrum of NADCs has changed, with prostate and breast cancers becoming the most common despite their lower SIR. Impact: These results confirm the need to maintain regular epidemiologic cancer monitoring in order to update screening guidelines.
- 1 October 2020
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 50 (7) , 582-589
E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 2: Health apps and smart devices
- 1 October 2020
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 50 (7) , 582-589
E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 2: Health apps and smart devices